1. Home
  2. LEGN vs VNO Comparison

LEGN vs VNO Comparison

Compare LEGN & VNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • VNO
  • Stock Information
  • Founded
  • LEGN 2014
  • VNO 1946
  • Country
  • LEGN United States
  • VNO United States
  • Employees
  • LEGN N/A
  • VNO N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • VNO Real Estate Investment Trusts
  • Sector
  • LEGN Health Care
  • VNO Real Estate
  • Exchange
  • LEGN Nasdaq
  • VNO Nasdaq
  • Market Cap
  • LEGN 7.0B
  • VNO 7.0B
  • IPO Year
  • LEGN 2020
  • VNO N/A
  • Fundamental
  • Price
  • LEGN $27.78
  • VNO $39.63
  • Analyst Decision
  • LEGN Strong Buy
  • VNO Hold
  • Analyst Count
  • LEGN 13
  • VNO 11
  • Target Price
  • LEGN $75.67
  • VNO $38.00
  • AVG Volume (30 Days)
  • LEGN 1.5M
  • VNO 1.3M
  • Earning Date
  • LEGN 05-13-2025
  • VNO 05-05-2025
  • Dividend Yield
  • LEGN N/A
  • VNO 1.87%
  • EPS Growth
  • LEGN N/A
  • VNO 248.25
  • EPS
  • LEGN N/A
  • VNO 0.52
  • Revenue
  • LEGN $728,303,000.00
  • VNO $1,929,890,000.00
  • Revenue This Year
  • LEGN $65.96
  • VNO N/A
  • Revenue Next Year
  • LEGN $52.55
  • VNO $5.12
  • P/E Ratio
  • LEGN N/A
  • VNO $75.54
  • Revenue Growth
  • LEGN 112.46
  • VNO 2.98
  • 52 Week Low
  • LEGN $29.27
  • VNO $22.42
  • 52 Week High
  • LEGN $60.87
  • VNO $46.63
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 29.61
  • VNO 61.90
  • Support Level
  • LEGN $30.25
  • VNO $38.63
  • Resistance Level
  • LEGN $33.30
  • VNO $40.73
  • Average True Range (ATR)
  • LEGN 1.78
  • VNO 1.16
  • MACD
  • LEGN -0.57
  • VNO 0.34
  • Stochastic Oscillator
  • LEGN 5.19
  • VNO 84.17

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About VNO Vornado Realty Trust

Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.

Share on Social Networks: